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Based on the available literature and the experiences collected from adult and paediatric patients treated
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Haemophilia Network worked together to reach a consensus on the management of bleeding events and
invasive procedures. RESULTS AND CONCLUSION Minor bleeding events and invasive procedures as-
sociated with low bleeding risk can be treated without factor replacement therapy in most cases, whereas
major bleeding events and high-risk surgery require additional factor VIII replacement at usual doses, at
least for the first days. Emicizumab treatment should be continued throughout the procedure and during
the postoperative period. Elective major surgery should be planned according to emicizumab dosing for
patients with a once-a-month posology. Of note, so far only few data are available on the management
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guidance will have to be regularly updated with growing experience. nbsp.
DOI: https://doi.org/10.4414/smw.2020.20422






The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives
4.0 International (CC BY-NC-ND 4.0) License.
Originally published at:
Fontana, Pierre; Alberio, Lorenzo; Albisetti, Manuela; Angelillo-Scherrer, Anne; Asmis, Lars M; Casini,
Alessandro; Gerber, Bernhard; Graf, Lukas; Hegemann, Inga; Korte, Wolfgang; Martinez, Maria; Studt,
Jan-Dirk; Tsakiris, Dimitrios A; Wuillemin, Walter A; Kremer Hovinga, Johanna A (2020). Management
of bleeding events and invasive procedures in patients with haemophilia A without inhibitors treated with
emicizumab. Swiss Medical Weekly, 150:w20422.
DOI: https://doi.org/10.4414/smw.2020.20422
2
Review article: Medical guidelines | Published 18 December 2020 | doi:10.4414/smw.2020.20422
Cite this as: Swiss Med Wkly. 2020;150:w20422
Management of bleeding events and invasive
procedures in patients with haemophilia A
without inhibitors treated with emicizumab
A consensus statement of the Working Party on Haemostasis of the Swiss Society of Haematology
and the Swiss Haemophilia Network
Fontana Pierrea, Alberio Lorenzob, Albisetti Manuelac, Angelillo-Scherrer Anned, Asmis Lars M.e, Casini Alessandroa, Gerber
Bernhardf, Graf Lukasg, Hegemann Ingah, Korte Wolfgangg, Martinez Mariai, Studt Jan-Dirkh, Tsakiris Dimitrios A.i, Wuillemin
Walter A.j, Kremer Hovinga Johanna A.d
a Division of Angiology and Haemostasis, University Hospitals of Geneva, Switzerland
b Service and Central Laboratory of Haematology, Lausanne University Hospital, Lausanne, Switzerland
c Division of Haematology, University Children’s Hospital, Zurich, Switzerland
d Department of Haematology and Central Haematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Switzerland
e Centre for perioperative Thrombosis and Haemostasis, Zurich, Switzerland
f Clinic of Haematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
g Cantonal Hospital of St Gallen, Switzerland
h Department of Medical Oncology and Haematology, University Hospital Zurich, Switzerland
i Diagnostic Haematology, Basel University Hospital, Basel, Switzerland
j Division of Hematology and Central Hematology Laboratory, Cantonal Hospital of Lucerne, Lucerne, and University of Bern, Switzerland
Summary
INTRODUCTION: Emicizumab (Hemlibra®, Hoffmann-La
Roche, Switzerland) is now available for haemophilia A
patients with or without factor VIII inhibitors. Management
of bleeding events and replacement therapy for invasive
procedures have to be adapted.
OBJECTIVE: To provide a practical guidance for the man-
agement of breakthrough bleeding events and elective
or urgent surgery in adult and paediatric patients with
haemophilia A without inhibitors treated with emicizumab.
METHODS: Based on the available literature and the ex-
periences collected from adult and paediatric patients
treated in Switzerland, the Working Party on Haemostasis
of the Swiss Society of Haematology and the Swiss
Haemophilia Network worked together to reach a consen-
sus on the management of bleeding events and invasive
procedures.
RESULTS AND CONCLUSION: Minor bleeding events
and invasive procedures associated with low bleeding risk
can be treated without factor replacement therapy in most
cases, whereas major bleeding events and high-risk
surgery require additional factor VIII replacement at usual
doses, at least for the first days. Emicizumab treatment
should be continued throughout the procedure and during
the postoperative period. Elective major surgery should be
planned according to emicizumab dosing for patients with
a once-a-month posology. Of note, so far only few data are
available on the management of major bleeds and surgery
in patients with haemophilia A treated with emicizumab
and this practical guidance will have to be regularly updat-
ed with growing experience.
Keywords: emicizumab, bleeds, invasive procedures,
guidelines
Introduction
Emicizumab (Hemlibra®, Hoffmann-La Roche, Basel,
Switzerland) is a recombinant, humanised bispecific mon-
oclonal antibody that substitutes for the pro-coagulant role
of factor VIII by bridging factor IXa to factor X. It is li-
censed for prophylactic treatment in patients with congen-
ital (usually severe) haemophilia A, with or without factor
VIII inhibitors. Emicizumab can be administered subcuta-
neously and has a half-life of approximately 30 days. This
allows a dosing of 1.5 mg/kg bodyweight once a week, or
3 mg/kg every two weeks, or 6 mg/kg once a month after
an initial weekly loading dose of 3 mg/kg for four consec-
utive weeks. The average effective plasma concentration
reached is around 50 µg/ml [1, 2]. Although the number of
spontaneous bleeds are dramatically decreased in patients
on emicizumab, breakthrough bleeds may still occur, and
invasive procedures including surgery may be necessary.
Guidelines for the management of bleeds and invasive pro-
cedures in patients treated with emicizumab and factor VI-
II inhibitors are available, and rely mostly on recombinant
factor VIIa to restore haemostasis [3–5]. However, spe-
cific recommendations for haemophilia A patients without
inhibitors treated with emicizumab, who may need factor
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VIII concentrates to treat breakthrough bleeds or prior to
invasive procedures, are scarce [6].
Methods
Our practical guidance is based on the available literature
and experiences with patients treated in Switzerland. Two
authors (PF and JAKH) reviewed the literature available in
PubMed using “emicizumab” as a keyword, as well as rel-
evant abstracts presented at major congresses (the Ameri-
can Society of Hematology, the European Association for
Haemophilia and Allied Disorders, the International So-
ciety on Thrombosis and Haemostasis and Gesellschaft
für Thrombose- und Hämostaseforschung) during the past
three years, and abstracts on file from Roche (last updated
30 June 2020). A first draft of the proposals was then cir-
culated and a consensus among all authors was reached.
Breakthrough bleeding events
Emicizumab does not fully restore haemostasis and pa-
tients may face bleeding events after (even minor) trauma
or, rarely, spontaneously. Patients treated with emicizumab
should have factor VIII concentrate available for emer-
gency situations. However, factor VIII treatment is not al-
ways necessary, and depends on the severity of the bleed,
on its localisation and on the possibility of specific local
treatment, such as compression or endoscopic procedures.
Notably, the amount of on-demand factor VIII used per
bleeding episode was comparable in a subset of 48 patients
during the non-interventional study period prior to study
enrolment and on study in the HAVEN 3 trial [7]. This sug-
gests that for most bleeds, factor VIII replacement thera-
py followed the same dosing as before switching to emi-
cizumab. Breakthrough bleeding events and their treatment
should be documented and recorded, for example in a na-
tional haemophilia registry by the treating haemophilia
centre (NCT02512250). The treatment with emicizumab
must not be interrupted and the posology should not be
altered if a bleed occurs, provided that the dose and ad-
ministration frequency are correct. Breakthrough bleeding
events, particularly spontaneous bleeds, may raise the issue
of poor efficacy of emicizumab prophylactic treatment.
Poor adherence with many missed injections over weeks
might be possible. Anti-drug antibodies [8] have been
rarely described [9] and have not been associated with the
occurrence of clinical events up to now. When decreased
efficacy of the drug is a concern, the activated partial
thromboplastin time (aPTT) can be measured, although,
because of the oversensitivity of the aPTT for emicizumab,
a prolonged aPTT will only occur at very low emicizumab
plasma concentrations [10]. Studying thrombin generation
may be an option, but no association with clinical efficacy
of emicizumab has been reported [4]. Finally, the determi-
nation of emicizumab plasma concentration using dedicat-
ed calibrators may be helpful [11, 12], and concentrations
below 40 µg/ml should be a concern, especially with once-
a-week or every two weeks dosing [2]. Of note, the lower
limit of a proposed “efficacious” range has been evaluated
as 30 µg/ml [13]. Management of breakthrough bleeding
events is summarised in figure 1.
Minor bleeding events
For mucosal bleeds, tranexamic acid alone should be pre-
scribed (2–4.5 g/24h for adults in two or three intakes, and
20–25 mg/kg/dose every 6–8 hours for children) for 1–3
days. In the case of minor traumatic bleeds, administration
of a single dose of a factor VIII concentrate (30–50 IU/kg)
should be considered, followed by a clinical evaluation 24
hours later. For target joint bleeds, although a single dose
of factor VIII concentrate may be sufficient in patients with
minimal joint damage, more intensive replacement therapy
may be required in patients with advanced joint disease.
Major bleeding events
Major bleeds, defined according to the ISTH criteria [14],
such as large muscle haematomas, bleeds associated with a
drop in haemoglobin ≥20 g/l and/or necessitating a trans-
fusion with at least two units of packed red blood cell con-
centrate, life-threatening bleeds or a bleed in a critical or-
gan must be immediately treated with an initial dose of
40–50 IU/kg of a factor VIII concentrate. Adherence to
emicizumab treatment should be questioned in the event of
a spontaneous major bleeding event and evaluation of the
emicizumab plasma concentration is desirable. Timing and
doses of the subsequent treatment should be adapted to the
type of bleed, the factor used (standard or extended half-
life) and the clinical course by maintaining a factor VIII
trough level of 0.6–0.8 IU/ml for at least the first 48 hours.
If the bleed is under control, a lower dose replacement
therapy regimen may be prescribed (providing that adher-
ence to emicizumab is not an issue) for up to 10 days af-
ter the major bleed. Tranexamic acid may be considered as
an additional treatment. Of note, in cases of severe bleeds
with massive transfusion, the plasma concentration of emi-
cizumab may decrease because of loss of the compound
due to bleeding and dilution with fluids and plasma re-
Figure 1: Summary of the proposed management of breakthrough
bleeding events in persons with haemophilia A factor VIII without
inhibitors and treated with emicizumab. ADA = anti-drug antibody.
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placement therapy, and assessing emicizumab concentra-
tion should be considered.
Of note, monitoring of actor VIII levels in patients treated
with emicizumab requires a chromogenic factor VIII assay
containing bovine factor X since emicizumab interferes
with one stage aPTT-based coagulation assays and with
chromogenic assays using human coagulation proteins
[13].
Invasive procedure and surgery
Invasive procedures or surgery may be necessary, whether
elective or emergency. In any case, the treatment with emi-
cizumab must not be interrupted or the posology altered,
provided that the dose and administration frequency are
correct. We suggest that an elective procedure should be
planned independently of the last emicizumab injection,
except for patients with a once-a-month posology and elec-
tive surgery associated with a high bleeding risk. Once-
a-month dosing is associated with emicizumab peaks and
troughs levels ranging from approximately 30–60 µg/ml
[2]. Therefore, the consensus is to perform high-risk elec-
tive surgery within 10 days after an emicizumab injection.
An alternative would be to switch from a once-a-month
posology to a once-a-week or once every other week regi-
men 1 month before the procedure and for 2 weeks there-
after. Clinical experience up to now includes mostly low-
risk procedures. However, a few cases of major surgeries
have been described with favourable outcome with factor
VIII replacement therapy. Management of invasive proce-
dures is summarised in figure 2.
Low-risk invasive procedures and minor surgery
In the HAVEN 1–4 trials, 214 minor surgeries were per-
formed in 113 study participants (108 minor surgeries per-
formed in patients without inhibitors), including 63 dental
and 34 central venous access procedures, without addition-
al administration of coagulation factor concentrates in 41
Figure 2: Summary of the proposed management of invasive pro-
cedures in persons with haemophilia A without factor VIII inhibitors
and treated with emicizumab.
and 25 procedures, respectively [15]. However, on 10 oc-
casions, post-interventional treatment was necessary [15].
Real-world post-licensing experience is limited, and re-
ports of 27 surgical procedures in patients without in-
hibitors have been published [16, 17]. The majority of pro-
cedures were minor surgeries – mostly removal of central
venous access devices in children (16/27 procedures) – and
were usually performed with a single dose of factor VI-
II concentrate prior to surgery, with two bleeding com-
plications leading to one additional factor VIII infusion.
No thrombotic events occurred. Altogether, emicizumab
seems to confer good haemostatic coverage for minor surg-
eries, often even without the necessity for coagulation fac-
tor administration.
For minor invasive procedures, including dental care, den-
tal avulsion, endoscopic procedures without biopsy and
joint infiltration, we suggest abstaining from prior factor
VIII product administration. Tranexamic acid should be
prescribed, at least for all dental procedures. If the bleeding
risk is a concern (e.g., in endoscopic procedures with biop-
sy, multiple dental avulsions), a factor VIII dose of 30 IU/
kg 30 minutes to 1 hour before the procedure can be con-
sidered.
High-risk invasive procedures and major surgery
In the HAVEN 1–4 trials, 19 major surgeries (including 8
major orthopaedic surgeries) were performed in 19 partic-
ipants (including 8 patients without inhibitors) [15]. Most
of these interventions were performed under prophylactic
coagulation factor replacement, with postoperative bleed-
ing in only one patient, and there were no thrombotic
complications. For arthroplasty (hip or knee) in patients
without inhibitors (n = 3), prophylaxis with factor VIII
concentrates was used for 7, 16 and 19 days [15]. In the
HAVEN 3 study, four patients had major orthopaedic
surgery and the mean cumulative factor VIII replacement
therapy was 135 IU/kg in the first 2 days after surgery, and
148 IU/kg over the following 5 days, suggesting decreased
trough levels from day 3 after surgery [1, 15]. More recent-
ly, a single-centre experience of surgery in 122 children
and adult patients treated with emicizumab for more than 6
months showed that the majority of orthopaedic surgeries
were performed with an initial factor VIII dose of 50 IU/kg
prior to surgery, replacement therapy once or twice a day
(usually 50 IU/Kg) for the following 2 to 5 days and low-
er-intensity replacement therapy thereafter [18]. For ma-
jor surgeries, adherence to the prophylactic treatment is of
particular importance and a laboratory evaluation of emi-
cizumab concentration, should be considered if compli-
ance is a concern. Although poor compliance may not in-
fluence the initial factor VIII replacement therapy, it may
influence factor VIII dosing during the postoperative days.
We suggest administration of 40–50 IU/kg of factor VI-
II 30 minutes to 1 hour prior surgery and to maintain a
factor VIII level above 0.6–0.8 IU/ml for 48–72 hours. In
some situations, continuous infusion of factor VIII may
be considered [19, 20]. We suggest that the decision to
use iterative boluses or continuous infusion should be tak-
en independently of emicizumab treatment. In the absence
of bleeding complications, a lower intensity replacement
therapy regimen with factor VIII trough levels of 0.5 IU/ml
for another 4–6 days, followed by a through level ranging
between 0.3 and 0.5 IU/ml for an additional 5–7 days may
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be adopted (total treatment duration 10–14 days). These
suggestions have to be adapted to the clinical situation and
the type of surgery. Of note, in cases of severe haemorrhag-
ic complications, the plasma concentration of emicizumab
may decrease because of loss of compound due to bleeding
and dilution with fluids and plasma replacement therapy,
and assessing emicizumab concentration should be consid-
ered.
We suggest that thromboprophylaxis similar to that for
persons with haemophilia A who are not on emicizumab
should be prescribed, according to the practice of each cen-
tre.
Discussion
The management of breakthrough bleeding events and in-
vasive procedures in patients treated with emicizumab
challenges haemophilia centres. Experience is still scarce,
with very few cases reported. Therefore, a common con-
sensus and practical guidance is important to have, but also
has to be updated regularly with growing experience. The
management of patients treated with emicizumab requires
a multidisciplinary approach and close collaboration with
the haemostasis laboratory is mandatory, as in most set-
tings involving patients with haemophilia.
Low-dose protocols for invasive procedures are considered
in several situations already, including non-factor replace-
ment therapies [21]. However, and according to the data
available up to now, a lower intensity dosing is described
for procedures associated with a low bleeding risk, where-
as in most of the major surgeries performed in patients
treated with emicizumab, factor VIII products were given
at usual doses, at least during the first 48 hours. Clinical
evaluation is of particular importance after major surgery
in order to adapt replacement therapy. Indeed, a lower re-
placement dose protocol may be associated with increased
bleeding complications, whereas a conventional protocol
may increase the risk of venous and arterial thrombotic
events, especially in geriatric patients with several comor-
bidities. Of note, no thrombotic event was described after
major surgery up to now. In vitro studies using a thrombin
generation assay showed a non-additive effect of factor VI-
II combined with emicizumab [22]. Indeed, emicizumab
has a lower binding affinity to factor IXa and factor X
than factor VIIIa and does not interfere with exogenous
factor VIII binding in the intrinsic tenase complex [23],
which probably contributes to its safety profile regarding
thrombotic events when both treatments are prescribed. In-
tegrative coagulation assays, such as a thrombin generation
assay or thrombelastography, may be useful for the adapta-
tion of periprocedural factor VIII replacement therapy [24]
and should be included as part of research projects for op-
timal management of patients on emicizumab.
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